MannKind Deal History & Licensing Activity
MannKind is a biotech headquartered in US. Over the past three years, MannKind has been involved in 3 licensing and acquisition transactions, with a primary focus on Peptides (2 deals). The company currently has 5 active clinical trials, primarily in Metabolic.
Deals (12mo)
2
Active Trials
5
Top Modality
Peptides
Focus Area
Metabolic
MannKind Recent Deal Activity
Licensing, acquisition, and partnership transactions involving MannKind in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| ROSE-010 Technosphere | Rose Pharma Inc. | Peptides | Preclinical | license | Sep 9, 2026 |
MannKind Pipeline Focus
Therapeutic areas and modalities where MannKind is most active based on deal history and clinical trial data.
Therapeutic Areas
MannKind Clinical Pipeline
MannKind has 5 active clinical trials across 2 development phases.
1
Not Applicable
4
Phase 2
See How Your Asset Matches MannKind's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About MannKind Licensing & Deal Activity
MannKind is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, MannKind ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for MannKind include Metabolic (6 deals and trials), Respiratory (2 deals and trials), and Cardiovascular (1 deal and trial). In terms of modality, MannKind has shown particular interest in peptides, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for MannKind and 700+ other biopharma companies. Use our Solidus to benchmark your asset against MannKind's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.